• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by CytoMed Therapeutics Limited

    7/3/25 8:00:25 AM ET
    $GDTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GDTC alert in real time by email
    6-K 1 form6-k.htm 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

    SECURITIES EXCHANGE ACT OF 1934

     

    For the month of July 2025.

     

    Commission File Number: 001-41677

     

    CytoMed Therapeutics Limited

    (Exact name of registrant as specified in its charter)

     

    1 Commonwealth Lane

    #08-22

    Singapore 149544

    (Address of Principal Executive Office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

     

     

     

     
     

     

    Annual Shareholders Meeting

     

    On June 26, 2025, at 12:00 p.m. local time (12:00 a.m. EST on , June 26, 2025), CytoMed Therapeutics Limited (the “Company”) held its 2025 annual meeting of shareholders (the “Annual Meeting”). Holders of zero ordinary shares of the Company were present in person and 7,624,197 ordinary shares of the Company were present by proxy at the annual meeting, representing approximately 66.06% of the total 11,540,000 outstanding ordinary shares and therefore constituting a quorum of at least two shareholders with ordinary shares outstanding and entitled to vote at the annual meeting as of the record date of June 23, 2025. The final voting results for each matter submitted to a vote of shareholders at the meeting are as follows:

     

      1. By an ordinary resolution, to receive and adopt the Directors’ Statement, the audited financial statements of the Company for the financial year ended December 31, 2024;
         
      2. By an ordinary resolution, to receive and adopt the audited financial statements in relation to Form 20-F for the financial year ended December 31, 2024;
         
      3. By an ordinary resolution, to approve the re-election of Dr. ZENG Jieming, who is retiring by rotation pursuant to Regulation 117 of the Constitution of the Company and who, being eligible, offers himself for re-election as Director;
         
      4. By an ordinary resolution, to approve the re-election of Mr. Mark LEONG Kei Wei who is retiring by rotation pursuant to Regulation 117 of the Constitution of the Company and who, being eligible, offers himself for re-election as Director;
         
      5. By an ordinary resolution, to approve the re-election of Prof. LOH Yuin Han who is retiring by rotation pursuant to Regulation 117 of the Constitution of the Company and who, being eligible, offers himself for re-election as Director;
         
      6. By an ordinary resolution, to ratify the appointment of WWC, P.C., as the Company’s independent registered public accounting firm for the financial year ending December 31, 2025 and that the Directors be empowered to fix the auditors’ remuneration in their absolute discretion;
         
      7. By an ordinary resolution, to ratify the appointment of KE Trust PAC as the Company’s independent registered public accounting firm for the financial year ending December 31, 2025 and that the Directors be empowered to fix the auditors’ remuneration in their absolute discretion;
         
      8. By an ordinary resolution, to approve payment of Directors’ fees of US$70,000 for the financial year ending December 31, 2025.
         
      9. By an ordinary resolution, to adjourn the Annual General Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of Proposal One, Proposal Two, Proposal Three, Proposal Four, Proposal Five, Proposal Six, Proposal Seven, Proposal Eight, Proposal Ten, and Proposal Eleven.

     

    2

     

     

      10. By an ordinary resolution, to resolve that:

     

    (a) Pursuant to Section 161 of the Singapore Companies Act 1967 (the “Singapore Companies Act”) the Directors be and are hereby authorized to issue such number of new ordinary shares in the capital of the Company as may be approved by the board of Directors (the “Board”), such shares to rank pari passu in all respects with the existing issued ordinary shares in the capital of the Company in connection with the initial public offering of the Company at the price(s) to be determined by the Board and on such terms and conditions as the Board may at any time and from time to time think fit and allot the same to such members of the public and/or private places who shall have applied for the shares in connection with the admission of the Company to Nasdaq, as the Board may decide.

     

    (b) Pursuant to Section 161 of the Companies Act 1967 and all applicable laws (including but not limited to the listing rules of Nasdaq (the “Nasdaq Listing Rules”)), the Directors be and are hereby authorized to: (a) (i) issue (in addition to the new ordinary shares referred to in paragraph (a) above) new ordinary shares whether by way of rights, bonus or otherwise; and/or (ii) make or grant offers, agreements or options (collectively “Instruments”) that might or would require new ordinary shares to be issued during the continuance of this authority or thereafter, including but not limited to the creation and issue of (as well as adjustments to) options, warrants, debentures or other instruments convertible into new ordinary shares, at any time and upon such terms and conditions and for such purposes and to such persons as the Directors may in their absolute discretion deem fit; and (b) (notwithstanding this authorization conferred may have ceased to be in force) issue new ordinary shares in pursuance of any Instruments made or granted by the Directors while this authorization was in force, provided that:

     

    (1) the aggregate number of new ordinary shares to be issued pursuant to such authority (including new ordinary shares to be issued in pursuance of the Instruments, made or granted pursuant to this authorization but excluding new ordinary shares which may be issued pursuant to any adjustments (“Adjustments”) effected under any relevant Instrument, which Adjustments shall be made in compliance with all applicable laws (including the Nasdaq Listing Rules) for the time being in force (unless such compliance has been waived by the Nasdaq) and the Constitution for the time being of the Company;

     

    (2) in exercising such authority, the Company shall comply with all applicable laws, including the provisions of the Act, the Nasdaq Listing Rules for the time being in force (unless such compliance has been waived by the Nasdaq) and the Constitution for the time being of the Company; and

     

    (3) unless revoked or varied by the Company in a general meeting by ordinary resolution, such authority shall continue in force until (i) the conclusion of the next annual general meeting of the Company or (ii) the date by which the next annual general meeting of the Company is required by law to be held, whichever is earlier.

     

      11. By a special resolution, alter Regulation 63(1) of the Constitution to remove the requirement to publish notice of general meetings in the daily press.

     

    All matters voted on at the Annual Meeting were approved as recommended by the Board of Directors of the Company. The number of votes cast with respect to each proposal, as applicable, is set forth below. The Company’s inspector of election reported the final vote of the stockholders as follows: 

     

    PROPOSAL #001 RECEIVE AND ADOPT THE DIRECTORS STATEMENT

     

    ***  FOR   AGAINST   ABS/WHD   BROKER NON-VOTES 
    BENEFICIAL   311,681    12,683    1,000    1,633,492 
    REGISTERED   5,665,341    0    0      
    TOTAL SHARES VOTED   5,977,022    12,683    1,000      
    % OF VOTED   99.78%   0.21%          
    % OF OUTSTANDING   51.79%   0.10%          
    % OF VOTED W/ABS/WHD   99.77%   0.21%   0.01%     
    % OF OUTSTNDG W/ABS/WHD   51.79%   0.10%   0.00%     

     

    3

     

     

    PROPOSAL #002 RECEIVE AND ADOPT THE AUDITED FINANCIAL STATEMENTS

     

    ***  FOR   AGAINST   ABS/WHD   BROKER NON-VOTES 
    BENEFICIAL   311,681    12,683    1,000    1,633,492 
    REGISTERED   5,665,341    0    0      
    TOTAL SHARES VOTED   5,977,022    12,683    1,000      
    % OF VOTED   99.78%   0.21%          
    % OF OUTSTANDING   51.79%   0.10%          
    % OF VOTED W/ABS/WHD   99.77%   0.21%   0.01%     
    % OF OUTSTNDG W/ABS/WHD   51.79%   0.10%   0.00%     

     

    PROPOSAL #003 APPROVE THE RE-ELECTION OF DR. ZENG JIEMING

     

    ***  FOR   AGAINST   ABS/WHD   BROKER NON-VOTES 
    BENEFICIAL   322,559    383    2,422    1,633,492 
    REGISTERED   5,665,341    0    0      
    TOTAL SHARES VOTED   5,987,900    383    2,422      
    % OF VOTED   99.99%   0.00%          
    % OF OUTSTANDING   51.88%   0.00%          
    % OF VOTED W/ABS/WHD   99.95%   0.00%   0.04%     
    % OF OUTSTNDG W/ABS/WHD   51.88%   0.00%   0.02%     

     

    PROPOSAL #004 APPROVE THE RE-ELECTION OF MR. MARK LEONG KEI WEI

     

    ***  FOR   AGAINST   ABS/WHD   BROKER NON-VOTES 
    BENEFICIAL   322,559    383    2,422    1,633,492 
    REGISTERED   5,665,341    0    0      
    TOTAL SHARES VOTED   5,987,900    383    2,422      
    % OF VOTED   99.99%   0.00%          
    % OF OUTSTANDING   51.88%   0.00%          
    % OF VOTED W/ABS/WHD   99.95%   0.00%   0.04%     
    % OF OUTSTNDG W/ABS/WHD   51.88%   0.00%   0.02%     

     

    PROPOSAL #005 APPROVE THE RE-ELECTION OF PROF. LOH YUIN HAN

     

    ***  FOR   AGAINST   ABS/WHD   BROKER NON-VOTES 
    BENEFICIAL   322,559    383    2,422    1,633,492 
    REGISTERED   5,665,341    0    0      
    TOTAL SHARES VOTED   5,987,900    383    2,422      
    % OF VOTED   99.99%   0.00%          
    % OF OUTSTANDING   51.88%   0.00%          
    % OF VOTED W/ABS/WHD   99.95%   0.00%   0.04%     
    % OF OUTSTNDG W/ABS/WHD   51.88%   0.00%   0.02%     

     

    PROPOSAL #006 RATIFY THE APPOINTMENT OF WWC, P.C. AS INDEP. REG. PUB. ACCT.

     

    ***  FOR   AGAINST   ABS/WHD   BROKER NON-VOTES 
    BENEFICIAL   1,926,452    5,247    27,157     
    REGISTERED   5,665,341    0    0      
    TOTAL SHARES VOTED   7,591,793    5,247    27,157      
    % OF VOTED   99.93%   0.06%          
    % OF OUTSTANDING   65.78%   0.04%          
    % OF VOTED W/ABS/WHD   99.57%   0.06%   0.35%     
    % OF OUTSTNDG W/ABS/WHD   65.78%   0.04%   0.23%     

     

    4

     

     

    PROPOSAL #007 RATIFY THE APPOINTMENT OF KE TRUST PAC AS INDEP. REG. PUB. ACCT.

     

    ***  FOR   AGAINST   ABS/WHD   BROKER NON-VOTES 
    BENEFICIAL   1,924,798    1,754    32,304      
    REGISTERED   5,665,341    0    0     
    TOTAL SHARES VOTED   7,590,139    1,754    32,304      
    % OF VOTED   99.97%   0.02%          
    % OF OUTSTANDING   65.77%   0.01%          
    % OF VOTED W/ABS/WHD   99.55%   0.02%   0.42%     
    % OF OUTSTNDG W/ABS/WHD   65.77%   0.01%   0.27%     

     

    PROPOSAL #008 APPROVE PAYMENT OF DIRECTORS FEES OF US$70,000

     

    ***  FOR   AGAINST   ABS/WHD   BROKER NON-VOTES 
    BENEFICIAL   321,758    1,606    2,000    1,633,492 
    REGISTERED   5,665,341    0    0      
    TOTAL SHARES VOTED   5,987,099    1,606    2,000      
    % OF VOTED   99.97%   0.02%          
    % OF OUTSTANDING   51.88%   0.01%         
    % OF VOTED W/ABS/WHD   99.93%   0.02%   0.03%     
    % OF OUTSTNDG W/ABS/WHD   51.88%   0.01%   0.01%     

     

    PROPOSAL #009 ADJOURN THE ANNUAL GENERAL MEETING TO A LATER DATE OR DATES

     

    ***  FOR   AGAINST   ABS/WHD   BROKER NON-VOTES 
    BENEFICIAL   1,907,144    51,712    0      
    REGISTERED   5,665,341    0    0      
    TOTAL SHARES VOTED   7,572,485    51,712    0      
    % OF VOTED   99.32%   0.67%          
    % OF OUTSTANDING   65.61%   0.44%         
    % OF VOTED W/ABS/WHD   99.32%   0.67%   0.00%     
    % OF OUTSTNDG W/ABS/WHD   65.61%   0.44%   0.00%     

     

    PROPOSAL #010 AUTHORIZE THE DIRECTORS TO ISSUE ORDINARY SHARES

     

    ***  FOR   AGAINST   ABS/WHD   BROKER NON-VOTES 
    BENEFICIAL   302,384    22,980    0    1,633,492 
    REGISTERED   5,665,341    0    0      
    TOTAL SHARES VOTED   5,967,725    22,980    0      
    % OF VOTED   99.61%   0.38%          
    % OF OUTSTANDING   51.71%   0.19%          
    % OF VOTED W/ABS/WHD   99.61%   0.38%   0.00%    
    % OF OUTSTNDG W/ABS/WHD   51.71%   0.19%   0.00%     

     

    PROPOSAL #011 REMOVE THE REQUIREMENT TO PUBLISH NOTICE OF GENERAL MEETINGS

     

    ***  FOR   AGAINST   ABS/WHD   BROKER NON-VOTES 
    BENEFICIAL   307,384    17,980    0    1,633,492 
    REGISTERED   5,665,341    0    0      
    TOTAL SHARES VOTED   5,972,725    17,980    0     
    % OF VOTED   99.69%   0.30%          
    % OF OUTSTANDING   51.75%   0.15%          
    % OF VOTED W/ABS/WHD   99.69%   0.30%   0.00%     
    % OF OUTSTNDG W/ABS/WHD   51.75%   0.15%   0.00%     

     

    5

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: July 3, 2025 CytoMed Therapeutics Limited
         
      By: /s/ CHOO Chee Kong
      Name: CHOO Chee Kong
      Title: Director and Chairman

     

    6

     

    Get the next $GDTC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GDTC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GDTC
    SEC Filings

    See more
    • SEC Form 6-K filed by CytoMed Therapeutics Limited

      6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)

      7/3/25 4:00:24 PM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by CytoMed Therapeutics Limited

      6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)

      7/3/25 8:00:25 AM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by CytoMed Therapeutics Limited

      EFFECT - CytoMed Therapeutics Ltd (0001873093) (Filer)

      6/24/25 12:15:22 AM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GDTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates

      SINGAPORE, April 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies without engaging in separate activities such as contract manufacturing, contract research, medical device development, or diagnostics, today announced its full-year ended December 31, 2024 financial results and provided clinical and corporate updates. We intend to be among the early pioneers of cellular immunotherapy treatment modalities to serve the ASEAN region and North Asia with

      4/28/25 4:05:00 PM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders

      SINGAPORE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company") today released a letter to shareholders from the Chairman of the Company's Board of Directors (the "Board") as it welcomes the new year ahead of its full-year audited results announcement due by end-April, the full text of which is provided below. All shareholders of CytoMed are encouraged to read. Dear Shareholders, The Board of CytoMed wishes you a healthy and prosperous Year of the Snake. The snake's ability to shed its skin is often compared to rebirth and renewal, representing adaptability and growth in Chinese mythology. The snake's calm and quiet nature also embodi

      2/6/25 7:20:39 AM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytoMed Therapeutics signs Business & Research Collaboration Agreement with India's SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India

      SINGAPORE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic off-the-shelf immunotherapies for the treatment of various cancers, today announced that it has entered into a Business & Research Collaboration Agreement ("BRCA") with Mumbai-based SunAct Cancer Institute Private Limited ("SunAct"), a company incorporated in the Republic of India ("India"). The BRCA forms a collaborative effort between CytoMed and SunAct to explore and investigate the safety, tolerability, poten

      1/6/25 7:00:00 AM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GDTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by CytoMed Therapeutics Limited (Amendment)

      SC 13G/A - CytoMed Therapeutics Ltd (0001873093) (Subject)

      5/23/24 6:10:52 AM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GDTC
    Leadership Updates

    Live Leadership Updates

    See more
    • CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank

      SINGAPORE, Oct. 03, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, has through its subsidiary, IPSC Depository Sdn Bhd, acquired the licence and certain assets of Cellsafe International Sdn Bhd (In Liquidation), a Malaysian cord blood bank. The acquisition includes (i) a cord blood banking licence issued by Malaysia's Ministry of Health, (ii) cryopreservation equipment with more than 12,000 cord blood units ("CBUs"

      10/3/24 7:00:00 AM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GDTC
    Financials

    Live finance-specific insights

    See more
    • CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates

      SINGAPORE, April 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies without engaging in separate activities such as contract manufacturing, contract research, medical device development, or diagnostics, today announced its full-year ended December 31, 2024 financial results and provided clinical and corporate updates. We intend to be among the early pioneers of cellular immunotherapy treatment modalities to serve the ASEAN region and North Asia with

      4/28/25 4:05:00 PM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

      SINGAPORE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers including blood and solid cancers has obtained full approval for its first-in-human Phase I clinical trial ("ANGELICA Trial") using its patented allogeneic chimeric antigen receptor T cell ("CAR-T cell") against several blood and solid tumors in collaboration with the National University Hospital ("NUH") of Singapore. The ANGELICA Trial is co-supported by the Singapore Minist

      10/7/24 7:00:00 AM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates

      Conference call via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT) https://us06web.zoom.us/meeting/register/tZMrcOmppj0sGdA37lASywTyixRflo9w1TZT SINGAPORE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived, cell-based allogeneic immunotherapies for the treatment of a broad range of cancers including blood and solid tumors, today announced six months ended June 30, 2024 financial results and provided clinical and corporate updates. "We are committed to advancing our "off-the-shelf" allogeneic c

      9/30/24 7:00:00 AM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care